An Extended Terminal Half-Life for Darbepoetin AlfaResults from a Single-Dose Pharmacokinetic Study in Patients with Chronic Kidney Disease not Receiving Dialysis

被引：0
|
作者：
Desmond Padhi
Liyun Ni
Blaire Cooke
Rafael Marino
Graham Jang
机构：
[1] Amgen Inc.,
来源：
Clinical Pharmacokinetics | 2006年 / 45卷
关键词：
Chronic Kidney Disease; Darbepoetin Alfa; Endogenous Erythropoietin; Single Subcutaneous Dose; Erythropoietic Agent;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：503 / 510
页数：7
相关论文
共 50 条
  • [1] An extended terminal half-life for darbepoetin alfa - Results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis
    Padhi, D
    Ni, LY
    Cooke, B
    Marino, R
    Jang, G
    CLINICAL PHARMACOKINETICS, 2006, 45 (05) : 503 - 510
  • [2] An extended terminal half-life for Aranesp® (darbepoetin alfa):: Results from a single-dose pharmacokinetic (PK) study in patients with chronic kidney disease (CKD)
    Padhi, D
    Jang, G
    Smith, B
    Marbury, T
    Cooke, B
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V255 - V255
  • [3] Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis
    Macdougall, IC
    Matcham, J
    Gray, SJ
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (03) : 576 - 581
  • [4] Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis dialysis
    Hoggard, Jeffrey
    Crouch, Thomas
    McMurray, Stephen
    Levine, Michael
    Prathikanti, Radha
    Scarlata, Debra
    Audhya, Paul
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (10) : 2023 - 2030
  • [5] The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis
    Abu-Alfa, Ali K.
    Sloan, Lance
    Charytan, Chaim
    Sekkarie, Mohammed
    Scarlata, Debra
    Globe, Denise
    Audhya, Paul
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (04) : 1091 - 1100
  • [6] Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis
    Barnett, AI
    Crémieux, PY
    PHARMACOTHERAPY, 2003, 23 (05): : 690 - 693
  • [7] Exposure-Response Modeling of Darbepoetin Alfa in Anemic Patients With Chronic Kidney Disease Not Receiving Dialysis
    Doshi, Sameer
    Chow, Andrew
    Perez Ruixo, Juan Jose
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 75S - 90S
  • [8] Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study
    Galle, Jan-Christoph
    Addison, Janet
    Suranyi, Michael G.
    Claes, Kathleen
    Di Giulio, Salvatore
    Guerin, Alain
    Herlitz, Hans
    Kiss, Istvan
    Farouk, Mourad
    Manamley, Nick
    Wirnsberger, Gerhard
    Winearls, Christopher
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (12) : 2073 - 2085
  • [9] Extended dosing with darbepoetin alfa in pre-dialysis chronic kidney disease (CKD) appears to be limited to patients with low dose requirements
    Wish, J
    Law, AW
    Schulman, KL
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) : A61 - A61
  • [10] A randomized crossover study of single biweekly administration of epoetin-alpha compared with darbepoetin-alpha in chronic kidney disease patients not receiving dialysis
    Na, Ha Young
    Lee, Yong-Kyu
    Shin, Sug-Kyun
    Yang, Dong-Ho
    Cheon, Woong
    Park, Jung-Hwan
    Lee, Jong-Ho
    Song, Jong-Oh
    Jo, Young-Il
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2014, 33 (04) : 210 - 216
12345